Novartis CEO Calms Concerns Over Zolgensma launch
Executive Summary
The Swiss major has posted a strong set of financials for the second quarter and Vas Narasimhan is pleased with the roll-out of Zolgensma, Mayzent and Piqray.
You may also be interested in...
Regenxbio: On The Cusp Of Becoming A Commercial Gene Therapy Player
Partnered with AbbVie on a wet AMD gene therapy, Regenxbio is also advancing wholly owned candidates for Duchenne muscular dystrophy and MPS I and MPS II.
One Way To Get Ahead: Biogen To Test Spinraza Given After Novartis’s Zolgensma
Biogen said some spinal muscular atrophy patients are currently being treated with Spinraza after receiving the Novartis gene therapy – its main competitor – so it will start a study of the risk/benefit in 2021.
Novartis's Zolgensma Finds Commercial Legs In A First For Gene Therapy
Zolgensma generated $160m in the third quarter, a strong launch for the gene therapy's first full quarter on the market.